Inhibitors

Edit

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

Nasdaq Globe Newswire 14 Jul 2026

SYDNEY, AUSTRALIA, July 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX ... .

Edit

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

PR Newswire 14 Jul 2026

... NLRP3 inhibitor ... The Phase 1 results reported by BioAge have positioned BGE-102 as a potential best-in-class NLRP3 inhibitor, with profound hsCRP reductions on a well-tolerated, once-daily oral dose.

Edit

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor (Immutep Ltd)

Public Technologies 14 Jul 2026

) Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor ... PD-1 pathway inhibitors, a key class of immunotherapies used in modern cancer treatment.

Edit

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (Form 6-K) (AstraZeneca plc)

Public Technologies 14 Jul 2026

AstraZeneca licenses novel EGFR inhibitor ... AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical ... Inhibitor Therapy.

Edit

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (AstraZeneca plc)

Public Technologies 14 Jul 2026

AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.

Edit

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress (Cadrenal Therapeutics Inc)

Public Technologies 13 Jul 2026

Its lead program, CAD-1005, is being investigated as a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder.

Edit

Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight

PR Newswire 13 Jul 2026

... classes, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, ionizing radiation emitters, and other agents used across different lines of therapy.

Edit

Quote of the Day by Dwayne Johnson: 'Check your ego at the door. The ego can be the great success inhibitor...'- Inspiring lessons on humility, overcoming ego, and achieving lasting success from the global superstar known as The Rock

The Times of India 10 Jul 2026

Quote of the Day by Dwayne Johnson ... .

Edit

JAK Inhibitor Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

GetNews 09 Jul 2026

DelveInsight’s “JAK Inhibitor Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the JAK Inhibitor pipeline landscape ... JAK Inhibitor Overview ... JAK Inhibitor Companies.

Edit

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis ...

Nasdaq Globe Newswire 08 Jul 2026

80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) ... .

Edit

FORM 6-K- Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model (BioLineRX Ltd)

Public Technologies 08 Jul 2026

). The text version of this document is not available ... Disclaimer. BioLineRX Ltd.

Edit

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model (Form 6-K) (BioLineRX Ltd)

Public Technologies 08 Jul 2026

Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived ... - Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at ... inhibitors, indicating that GLIX1.

Edit

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

PR Newswire 08 Jul 2026

Ovarian cancer remains a major therapeutic challenge, particularly in homologous recombination (HR)-proficient disease where PARP inhibitors (PARPi) presently have limited efficacy, as well as for patients with platinum-resistance.

Edit

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model (BioLineRX Ltd)

Public Technologies 08 Jul 2026

Ovarian cancer remains a major therapeutic challenge, particularly in homologous recombination (HR)-proficient disease where PARP inhibitors (PARPi) presently have limited efficacy, as well as for patients with platinum-resistance.

Edit

SERES THERAPEUTICS ANNOUNCES EARLY CLINICAL DATA SHOWING POTENTIAL FOR SER-155 IN IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC), A FREQUENT ADVERSE REACTION THAT FORCES MANY PATIENTS TO HALT CANCER TREATMENT (Form 8-K) (Seres Therapeutics Inc)

Public Technologies 08 Jul 2026

IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC), A FREQUENT ADVERSE REACTION ... About Immune Checkpoint Inhibitors (ICIs) ... About Immune checkpoint inhibitor-related enterocolitis (irEC).

Podcasts:

Latest News for: inhibitors

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor (Immutep Ltd)

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (Form 6-K) (AstraZeneca plc)

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (AstraZeneca plc)

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress (Cadrenal Therapeutics Inc)

Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight

Quote of the Day by Dwayne Johnson: 'Check your ego at the door. The ego can be the great success inhibitor...'- Inspiring lessons on humility, overcoming ego, and achieving lasting success from the global superstar known as The Rock

JAK Inhibitor Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis ...

FORM 6-K- Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model (BioLineRX Ltd)

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model (Form 6-K) (BioLineRX Ltd)

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model (BioLineRX Ltd)

SERES THERAPEUTICS ANNOUNCES EARLY CLINICAL DATA SHOWING POTENTIAL FOR SER-155 IN IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC), A FREQUENT ADVERSE REACTION THAT FORCES MANY PATIENTS TO HALT CANCER TREATMENT (Form 8-K) (Seres Therapeutics Inc)

Article Search

EXPLORE WN.com